

Abstract

Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.